Drugs Containing Excipient (Inactive Ingredient) PROPYLENE OXIDE

« Back to Dashboard

Generic drugs containing PROPYLENE OXIDE excipient

Company	Ingredient	NDC	Excipient
TriRx Huntsville Pharmaceutical Services LLC	diazoxide oral suspension	80432-057	PROPYLENE OXIDE

Propylene Oxide Market Dynamics, Pharmaceutical Exposure, and Financial Trajectory

Last updated: August 31, 2026

Propylene oxide is a large-volume industrial intermediate, not a conventional pharmaceutical excipient. Its pharmaceutical relevance is indirect: it is a key feedstock for propylene glycol, polyether polyols, and glycol ethers used in drug formulations, medical products, packaging, and manufacturing equipment. Market performance is driven primarily by polyurethane demand, propylene and chlorine economics, global capacity utilization, environmental regulation, and downstream propylene glycol consumption.

The financial outlook is mixed. Volume demand should grow with construction, refrigeration, automotive, appliances, and pharmaceutical manufacturing. Margins remain exposed to cyclical overcapacity, volatile propylene prices, energy costs, and regulatory controls tied to carcinogenicity and occupational exposure. Pharmaceutical demand provides quality-sensitive business but is too small to determine global propylene oxide pricing.

What is propylene oxide and how is it used in pharmaceutical manufacturing?

Propylene oxide, also known as 1,2-epoxypropane, is an epoxide with the chemical formula C3H6O and CAS Registry Number 75-56-9. It is a volatile, highly reactive and flammable liquid used mainly as a chemical intermediate.

Attribute	Data
Chemical name	Propylene oxide
CAS number	75-56-9
Molecular formula	C3H6O
Principal industrial role	Intermediate for propylene glycol and polyether polyols
Major downstream products	Polyurethane systems, propylene glycol, glycol ethers
Pharmaceutical status	Not generally used as a finished-drug excipient
Main regulatory concern	Carcinogenicity, mutagenicity, flammability and occupational exposure
Primary production routes	Chlorohydrin process and hydroperoxide-based co-product processes

Propylene oxide is not equivalent to propylene glycol. Propylene glycol is a widely used pharmaceutical excipient, solvent, humectant, plasticizer and vehicle. Propylene oxide is the upstream chemical used in some propylene glycol production routes.

Direct use of propylene oxide in a medicinal formulation would present a substantial regulatory problem because of its toxicity profile and chemical reactivity. Residual propylene oxide would be treated as a process-related impurity requiring strict control rather than as a functional inactive ingredient.

The U.S. Environmental Protection Agency classifies propylene oxide as likely to be carcinogenic to humans based on inhalation exposure evidence. The International Agency for Research on Cancer classifies it as probably carcinogenic to humans, Group 2A.[1,2]

How large is the propylene oxide market?

Public market studies generally place global propylene oxide demand in the high-single-digit to low-double-digit million-tonne range, with market value estimates varying materially by inclusion of derivatives, regional price assumptions and merchant versus captive production.

The largest demand pools are:

Downstream application	Approximate role in demand	Pharmaceutical connection
Polyether polyols	Largest application	Indirect, through medical devices, insulation and equipment
Propylene glycol	Major application	High, because propylene glycol is a pharmaceutical excipient
Glycol ethers	Smaller application	Solvents and cleaning agents used in manufacturing
Other chemicals	Smaller application	Resins, surfactants and specialty intermediates

Demand growth is linked to:

• Polyurethane foam used in buildings, appliances, refrigeration and vehicles.
• Propylene glycol used in food, cosmetics, pharmaceuticals and industrial fluids.
• Medical-device and pharmaceutical production requiring high-purity downstream chemicals.
• Growth in cold-chain infrastructure and energy-efficient insulation.
• Expansion of emerging-market construction and automotive manufacturing.

Pharmaceutical consumption is commercially important for high-purity propylene glycol and related derivatives, but it does not represent the primary market for propylene oxide itself.

What is driving the financial trajectory for propylene oxide?

Propylene oxide earnings depend more on chemical-cycle conditions than on pharmaceutical demand.

Feedstock and process economics

Propylene is the principal hydrocarbon feedstock. Producers using the chlorohydrin route also carry exposure to chlorine, caustic soda, wastewater treatment and environmental compliance costs. Hydroperoxide routes can produce styrene monomer, tert-butanol or methyl tert-butyl ether as co-products. Their economics therefore depend on several product markets rather than propylene oxide alone.

A simplified margin structure is:

Propylene oxide margin = selling price of propylene oxide minus propylene, oxidant or chlorine-related costs, utilities, logistics, maintenance and compliance costs.

The most profitable producers typically have:

• Integrated propylene supply.
• Captive downstream propylene glycol or polyol demand.
• Access to low-cost power and steam.
• Co-product outlets.
• Regional logistics advantages.
• High plant utilization.

Capacity additions and cyclicality

The main financial risk is capacity growth outpacing demand. New propylene oxide and derivative capacity can pressure contract prices even when end-market volumes increase. This effect is strongest in Asia, where chemical producers have expanded integrated propylene, propylene oxide, propylene glycol and polyurethane chains.

When construction and automotive markets weaken, polyurethane demand falls rapidly. Propylene glycol demand is more defensive because pharmaceutical, food and personal-care applications carry higher specification requirements. Those markets, however, are insufficient to offset a major industrial downturn.

Product quality and qualification premiums

Pharmaceutical-grade propylene glycol commands a quality premium over industrial material. Buyers may require:

• Pharmacopoeial compliance.
• Low aldehyde and peroxide content.
• Controlled heavy metals.
• Validated impurity profiles.
• Batch traceability.
• Good Manufacturing Practice controls.
• Change-control commitments.
• Auditable supply-chain documentation.

These requirements create switching costs for downstream propylene glycol suppliers. They do not create the same level of protection for commodity propylene oxide producers because the molecule is normally converted before entering the pharmaceutical supply chain.

Which companies are major propylene oxide producers?

The competitive landscape includes integrated oil and chemical companies, specialty chemical producers and regional manufacturers. Major participants have included LyondellBasell Industries, BASF, Dow, Indorama Ventures, Repsol, SKC, Sinopec, China Petroleum & Chemical Corporation affiliates, Mitsubishi Chemical, Sumitomo Chemical and several Chinese producers.

Company or group	Strategic position
LyondellBasell	Integrated propylene oxide, propylene glycol and polyols; North American and European exposure
BASF	Integrated European and Asian chemical production; downstream polyurethane and specialty chemical businesses
Dow	Propylene oxide and polyether polyol exposure linked to polyurethane systems
Indorama Ventures	Broad petrochemical and intermediate portfolio, including propylene glycol-related products
Repsol	Integrated European petrochemical production
Sinopec and other Chinese producers	Large domestic capacity and expanding integrated value chains
SKC and Mitsubishi Chemical	Regional specialty and intermediate production

Company filings generally report propylene oxide within broader intermediates, industrial solutions or polyurethanes segments. Standalone revenue and EBITDA disclosure is uncommon. As a result, investor analysis must use segment margins, production volumes, plant utilization, announced capacity and derivative pricing rather than a clean company-by-company propylene oxide income statement.[3-6]

What is the pharmaceutical demand outlook for propylene oxide derivatives?

The strongest pharmaceutical linkage is through propylene glycol.

Propylene glycol is used in:

• Oral liquids and syrups.
• Topical creams and gels.
• Injectable formulations where permitted by product-specific safety assessments.
• Soft-gel and liquid-filled dosage forms.
• Veterinary medicines.
• Medical-device fluids and processing systems.
• Solvent systems for active pharmaceutical ingredients.
• Humectant and plasticizer applications.

The pharmaceutical market is governed by downstream material specifications. A drug manufacturer generally purchases qualified propylene glycol from a pharmaceutical excipient supplier, not propylene oxide from an upstream commodity producer.

Demand is likely to remain resilient because propylene glycol is embedded in established formulations and manufacturing processes. The principal risks are substitution, formulation redesign, supply qualification failures and safety concerns involving impurities such as diethylene glycol and ethylene glycol. FDA has repeatedly emphasized testing and supplier controls for these contaminants in pharmaceutical and other consumer products.[7]

What FDA regulatory status applies to propylene oxide?

Propylene oxide does not have the regulatory profile of an approved pharmaceutical excipient.

Regulatory question	Status
FDA-approved active pharmaceutical ingredient	No
Standard pharmaceutical inactive ingredient	Not generally recognized as an intentional formulation excipient
FDA Orange Book listing	Not applicable
FDA reference-listed drug	Not applicable
Paragraph IV litigation	Not applicable
Biosimilar pathway	Not applicable
Pharmaceutical manufacturing concern	Residual impurity, worker exposure and process safety
Key downstream FDA-relevant material	Propylene glycol and other qualified excipients

The FDA Inactive Ingredient Database is used to identify inactive ingredients in approved drug products. Propylene oxide is not a normal formulation component comparable to propylene glycol, polyethylene glycol or glycerin.[8]

Where propylene oxide is used in an upstream manufacturing process, the finished pharmaceutical manufacturer must control residuals through process validation, analytical testing and applicable impurity specifications. The relevant regulatory question is not whether propylene oxide has an Orange Book patent listing. It is whether any residual level is justified, controlled and compatible with the finished product’s safety profile.

What patents protect propylene oxide production and downstream applications?

Patent protection exists around production technologies, catalysts, oxidation systems, reactor configurations, separation processes and derivative manufacturing. The main patent categories include:

1. Direct oxidation and hydrogen-peroxide processes.
2. Chlorohydrin process improvements.
3. Catalyst compositions and regeneration methods.
4. Propylene oxide purification and impurity removal.
5. Co-product integration with styrene monomer or tert-butanol.
6. Propylene glycol and polyether polyol production.
7. Polyurethane formulations and processing systems.
8. High-purity downstream materials for regulated markets.

The core chemical compound is long off patent. Commercial protection instead depends on process patents, trade secrets, plant integration, catalyst know-how and customer qualification.

How strong is the propylene oxide patent estate?

The patent estate is strongest where it protects:

• Lower-cost oxidation routes.
• Reduced waste and energy consumption.
• Higher catalyst selectivity.
• Improved safety performance.
• Co-product economics.
• High-purity purification.
• Integrated plant designs.

Process patents can be commercially meaningful even when the molecule itself is commoditized. Their value depends on enforceability, freedom-to-operate analysis, geographic coverage and whether competing routes provide an economically viable substitute.

Trade secrets are particularly important because operating conditions, catalyst handling, purification controls and plant-integration data may be difficult to reconstruct from published patents.

What patent litigation, Paragraph IV challenges and settlements affect propylene oxide?

Conventional pharmaceutical patent litigation is not a material feature of the propylene oxide market.

There is no branded propylene oxide drug, no generic-drug approval pathway for the chemical, and no meaningful Paragraph IV challenge structure. Patent disputes are more likely to involve:

• Chemical process infringement.
• Catalyst technology.
• Polyurethane formulations.
• Propylene glycol purification.
• Supply agreements and technology licensing.
• Environmental permits and plant operating rights.

Settlement agreements, where they occur, are generally commercial or technology-related rather than Hatch-Waxman settlements. Biosimilar risk is also irrelevant because propylene oxide is a small molecule industrial chemical, not a biologic.

What manufacturing and intellectual-property barriers affect supply?

The main barriers are capital intensity, safety infrastructure and regulatory compliance.

A commercial plant requires:

• High-pressure or specialized oxidation equipment.
• Hazardous-material storage and transport systems.
• Explosion protection.
• Chlorine or peroxide handling capability, depending on process.
• Wastewater and emissions controls.
• Trained operators.
• Downstream derivative integration.
• Reliable propylene supply.

The capital cost and process complexity limit new entrants. The competitive threat is greater from existing integrated chemical companies expanding capacity than from pharmaceutical companies entering production.

Geographic coverage is concentrated in North America, Western Europe and Asia. China has increased its share of global chemical capacity, while Europe faces higher energy costs and tighter emissions requirements. North American producers benefit from feedstock integration and comparatively favorable energy economics, although logistics and export constraints affect regional pricing.

When does propylene oxide lose exclusivity?

Propylene oxide has already lost compound-level exclusivity. It is a mature commodity chemical with multiple commercial production routes and numerous global suppliers.

Remaining exclusivity can apply to individual process patents, catalyst systems, plant technologies, purification methods or proprietary derivative formulations. Those rights expire on a patent-by-patent and jurisdiction-by-jurisdiction basis. They do not prevent generic production of propylene oxide as a chemical.

What generic launch risks exist for pharmaceutical users?

The relevant risk is not generic launch but supply interruption and excipient substitution.

Pharmaceutical manufacturers face four main risks:

• A qualified propylene glycol supplier loses production capacity.
• A supplier changes its manufacturing process or site without adequate notification.
• Contamination affects pharmaceutical-grade material.
• Regulatory restrictions increase testing or disqualify a source.

A second-source strategy can reduce risk, but qualifying another pharmaceutical excipient supplier requires analytical comparability, stability assessment, documentation review and often regulatory notification. Commodity availability does not guarantee pharmaceutical acceptability.

How does propylene oxide compare with competing chemical intermediates?

Intermediate	Pharmaceutical relevance	Market risk	Strategic profile
Propylene oxide	Mainly indirect through propylene glycol	High cyclicality	Large-volume, integrated commodity
Ethylene oxide	Directly linked to PEGs, surfactants and sterilization	High regulatory exposure	Larger and more diversified derivative base
Propylene glycol	Direct pharmaceutical excipient	Lower volatility than propylene oxide	Quality-sensitive downstream product
Glycerin	Direct pharmaceutical excipient	Supply and contamination risk	Renewable and petrochemical supply options
Polyethylene glycol	Direct excipient and drug-delivery material	Specialty-grade qualification risk	Higher value per tonne

Propylene oxide is more exposed to construction and polyurethane cycles than glycerin or polyethylene glycol. Its pharmaceutical value chain is therefore less defensive than its downstream pharmaceutical applications might suggest.

What is the five-year financial outlook for propylene oxide?

The base case is moderate volume growth with uneven margins.

Period	Expected market condition
Near term	Pricing pressure from capacity, weak construction and variable automotive demand
Mid term	Recovery tied to polyurethane, appliances, refrigeration and infrastructure
Longer term	Higher compliance costs, process innovation and regional supply-chain restructuring
Pharmaceutical derivatives	Stable growth in qualified propylene glycol and specialty grades
Producer profitability	Strongest for integrated, low-cost facilities with downstream outlets

Upside factors include stronger construction, appliance replacement, cold-chain investment, automotive recovery and improved polyurethane demand. Downside factors include Chinese overcapacity, recession, lower plant utilization, feedstock inflation, energy-price shocks and tighter carcinogen or emissions controls.

For investors, the best indicators are propylene spreads, polyurethane operating rates, propylene glycol contract pricing, new capacity announcements, plant shutdowns, producer inventory and segment-level operating margins.

Key Takeaways

• Propylene oxide is an industrial intermediate, not a conventional pharmaceutical excipient.
• Its primary pharmaceutical connection is the production of propylene glycol and related downstream materials.
• Commodity demand is dominated by polyurethane and construction-linked applications.
• The molecule has no meaningful Orange Book, Paragraph IV or biosimilar exposure.
• Process patents, catalyst technologies, trade secrets and plant integration provide the main competitive barriers.
• Pharmaceutical-grade downstream products carry qualification premiums and switching costs.
• Financial performance is cyclical and depends on feedstocks, capacity utilization, energy costs and derivative demand.
• Integrated producers with captive propylene glycol or polyol capacity have the strongest margin protection.
• Supply-chain quality and contamination controls are more important to pharmaceutical buyers than compound-level patent exclusivity.

FAQs

Is propylene oxide safe for use in medicines?

Propylene oxide is not normally used as an intentional medicine excipient. Its toxicity, reactivity and carcinogenicity profile make residual control and occupational safety central concerns.

Is propylene oxide the same as propylene glycol?

No. Propylene oxide is an upstream epoxide intermediate. Propylene glycol is a downstream chemical used as a pharmaceutical solvent, humectant and vehicle.

Can pharmaceutical companies buy propylene oxide directly?

They can purchase it for controlled industrial processes, but finished pharmaceutical manufacturers generally buy qualified downstream materials such as pharmaceutical-grade propylene glycol.

Does propylene oxide have an FDA Drug Master File?

A drug master file may exist for a supplier’s manufacturing process or a downstream pharmaceutical-grade material, but propylene oxide itself is not an FDA-approved drug excipient with a standard Orange Book product listing.

Which factor presents the greatest investment risk in propylene oxide?

Overcapacity is the central commercial risk. New integrated capacity can reduce utilization and margins even when underlying demand continues to grow.

References

1. U.S. Environmental Protection Agency. (2016). Toxicological review of propylene oxide (CAS No. 75-56-9). Integrated Risk Information System.

2. International Agency for Research on Cancer. (1994). Propylene oxide. In IARC monographs on the evaluation of carcinogenic risks to humans: Some industrial chemicals. World Health Organization.

3. BASF SE. (2023). Annual report 2023. Ludwigshafen, Germany.

4. Dow Inc. (2023). 2023 annual report. Midland, MI.

5. LyondellBasell Industries N.V. (2023). Annual report 2023. Houston, TX.

6. Indorama Ventures Public Company Limited. (2023). Annual report 2023. Bangkok, Thailand.

7. U.S. Food and Drug Administration. (2023). FDA alerts drug manufacturers to the risk of contamination with diethylene glycol and ethylene glycol. Silver Spring, MD.

8. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Silver Spring, MD.